Last reviewed · How we verify
Insulin glargine plus insulin analogues
Insulin glargine plus insulin analogues is a Small molecule drug developed by IRCCS San Raffaele. It is currently FDA-approved. Also known as: Insulin glargine plus short acting insulin analogues, Insulin glargine plus hypoglycemic agents.
At a glance
| Generic name | Insulin glargine plus insulin analogues |
|---|---|
| Also known as | Insulin glargine plus short acting insulin analogues, Insulin glargine plus hypoglycemic agents |
| Sponsor | IRCCS San Raffaele |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before (PHASE3)
- Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy (PHASE3)
- Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study) (PHASE4)
- Human Versus Analogue Insulin in Patients After Pancreatectomy. (PHASE4)
- A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients (PHASE4)
- Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines (NA)
- Normalization of Fasting Glucose and the Incidence of Restenosis After Peripheral Angioplasty (PHASE4)
- Extension to Study HMR1964A/3011 in Belgium (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin glargine plus insulin analogues CI brief — competitive landscape report
- Insulin glargine plus insulin analogues updates RSS · CI watch RSS
- IRCCS San Raffaele portfolio CI
Frequently asked questions about Insulin glargine plus insulin analogues
What is Insulin glargine plus insulin analogues?
Insulin glargine plus insulin analogues is a Small molecule drug developed by IRCCS San Raffaele.
Who makes Insulin glargine plus insulin analogues?
Insulin glargine plus insulin analogues is developed and marketed by IRCCS San Raffaele (see full IRCCS San Raffaele pipeline at /company/irccs-san-raffaele).
Is Insulin glargine plus insulin analogues also known as anything else?
Insulin glargine plus insulin analogues is also known as Insulin glargine plus short acting insulin analogues, Insulin glargine plus hypoglycemic agents.
What development phase is Insulin glargine plus insulin analogues in?
Insulin glargine plus insulin analogues is FDA-approved (marketed).
Related
- Manufacturer: IRCCS San Raffaele — full pipeline
- Also known as: Insulin glargine plus short acting insulin analogues, Insulin glargine plus hypoglycemic agents
- Compare: Insulin glargine plus insulin analogues vs similar drugs
- Pricing: Insulin glargine plus insulin analogues cost, discount & access